Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.

about

Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.

Item

http://www.wikidata.org/entity/Q35956862

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prospective clinical study of ...... matology Oncology Study Group.

@ast

Prospective clinical study of ...... matology Oncology Study Group.

@en

type

Item

label

Prospective clinical study of ...... matology Oncology Study Group.

@ast

Prospective clinical study of ...... matology Oncology Study Group.

@en

prefLabel

Prospective clinical study of ...... matology Oncology Study Group.

@ast

Prospective clinical study of ...... matology Oncology Study Group.

@en

P1476

Prospective clinical study of ...... matology Oncology Study Group.

@en

P2093

Akio Nakajima

http://www.w3.org/2001/XMLSchema#string

Haruka Iwao

http://www.w3.org/2001/XMLSchema#string

Ippei Sakamaki

http://www.w3.org/2001/XMLSchema#string

Jun Murakami

http://www.w3.org/2001/XMLSchema#string

Masao Tanaka

http://www.w3.org/2001/XMLSchema#string

Miyuki Miki

http://www.w3.org/2001/XMLSchema#string

Nozomi Otsuki

http://www.w3.org/2001/XMLSchema#string

Shinji Kishi

http://www.w3.org/2001/XMLSchema#string

Takafumi Kawanami

http://www.w3.org/2001/XMLSchema#string

Takanori Ueda

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.

Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.

Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.

Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

P2888

s12032-015-0677-9

P304

232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-015-0677-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281055093

http://www.w3.org/2001/XMLSchema#string

P698

26275804

http://www.w3.org/2001/XMLSchema#string

P932

4537487

http://www.w3.org/2001/XMLSchema#string